摘要
目的:系统评价美洛昔康治疗类风湿关节炎与骨关节炎的临床疗效和安全性。方法:检索并选取国内公开发表的有关美洛昔康治疗类风湿关节炎和骨关节炎随机对照试验文献,应用Jadad评分法进行质量评价,运用Meta分析方法进行统计。结果:共有15项研究符合纳入标准。与对照组比较,美洛昔康治疗类风湿关节炎疗效的合并效应量OR值为1.07(95%CI为0.82～1.40);美洛昔康治疗骨关节炎疗效的合并效应量OR值为1.25(95%CI为0.86～1.82);安全性的合并效应量OR值为0.75(95%CI为0.61～0.92)。结论:美洛昔康治疗类风湿关节炎和骨关节炎的临床疗效总体上与对照组相当,而不良反应发生率总体上低于对照组。
OBJECTIVE： To evaluate the curative effect and safety of meloxicam in treating rheumatoid arthritis （RA） and osteoarthritis （OA）. METHODS： The domestic publicly published literature about the randomized controlled trials （RCT） on meloxicam for rheumatoid arthritis and osteoarthritis were retrieved for quality evaluation using Jadad score and statistical analysis using meta analysis. RESULTS： 15 RCTs accorded with the inclusion criteria. Comparing with the control group, the combined OR of the curative efficacy of meloxicam was 1.07 （95% CI = 0.82-1.40） for rheumatoid arthritis versus 1.25 （95 % CI = 0.86- 1.82） for osteoarthritis. The combined OR of the safety was 0.75（95% CI = 0.61- 0.92）. CONCLUSION ： The curative effect of meloxicam was equivalent to its control on the whole in treating rheumatoid arthritis and osteoarthritis; however, meloxicam had lower incidence of adverse drug reactions.
出处
《中国药房》
CAS
CSCD
北大核心
2009年第23期1796-1798,共3页
China Pharmacy
